The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Outcomes of renal transplantation in patients with AL amyloidosis
Nelson Leung, Mayo Clinic, Rochester, MN, shares the key results of a study investigating the long-term outcomes of renal transplantation in patients with AL amyloidosis. Overall, the study demonstrated that patients who reached a very good partial response (VGPR) or better had an improved survival, suggesting that patients with kidney failure who do not have significant heart involvement and achieve a VGPR or better after therapy should undergo kidney transplantation. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
